Nant COVID Vaccine Cross Reactivity

Smart overview of the Invention

Recombinant SARS-CoV2 vaccine compositions are designed to exhibit unexpected cross-reactivity against various coronaviruses, including SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV. These compositions not only target SARS-CoV2 but also generate cross-reactive memory B and T cells that can respond to a broad range of coronaviruses.

Method of Eliciting Immune Response

A method is proposed for inducing a cross-reactive immune response against coronaviruses. This involves administering a recombinant vaccine that includes two components: one encoding the nucleocapsid protein (N) fused with an endosomal targeting sequence and another encoding the spike protein (S). The vaccination aims to activate immune responses that can recognize multiple coronavirus variants.

Generation of Antibodies and T Cells

The vaccine composition is intended to stimulate the production of antibodies that bind to different variants of SARS-CoV2 and other coronaviruses. Additionally, it aims to generate cytotoxic T cells capable of targeting cells infected with these viruses, enhancing the immune system's ability to combat infections.

Formulation Variations

The recombinant vaccine can be formulated in various ways, including as a recombinant virus or RNA. Specific formulations may involve an adenoviral vector or polycistronic RNA that incorporates both the N and S proteins. The vaccine can be administered in either prime-boost strategies or as a standalone boost following other vaccine types.

Memory Cell Development

A further aspect focuses on generating memory B and T cells with cross-reactivity against multiple coronaviruses. The administration of the recombinant vaccine aims to facilitate the formation of these memory cells, which are crucial for long-term immunity against threats posed by diverse coronaviruses, including those not previously encountered.